Drug Details
| General Information of the Drug (ID: DR3078) | ||||
|---|---|---|---|---|
| Name |
1,25-dihydroxyvitamin D3
|
|||
| Synonyms |
calcitriol; Rocaltrol; 32222-06-3; Calcijex; Topitriol; 1alpha,25-Dihydroxyvitamin D3; Silkis; Soltriol; 1alpha,25-Dihydroxycholecalciferol; Calcitriolum; Dihydroxyvitamin D3; 1,25-DHCC; 1,25-Dihydroxyvitamin D; Vectical; 1,25-DIHYDROXYCHOLECALCIFEROL; 1,25-Dihydroxyvitamin D3; 1alpha,25-Dihydroxyvitamin D; 1-alpha,25-Dihydroxyvitamin D3; Calcitriolum [INN-Latin]; UNII-FXC9231JVH; 1alpha,25(OH)2D3; DN-101; 1,25-Dihydroxycholecaliferol; CCRIS 5522; Ro 21-5535; HSDB 3482; 1-alpha,25-Dihydroxycholecalciferol; EINECS 250-963-8; DN 101; Calcitriol (chemotherapy-induced alopecia); Calcitriol (chemotherapy-induced alopecia), Cytotech Labs; Calcitriol (API-31543, drug-induced alopecia), Cytotech Labs; 1alpha,25 dihydroxyvitamin D(3)
Click to Show/Hide
|
|||
| Molecular Type |
Small molecule
|
|||
| Disease | Congenital alopecia [ICD-11: LC30] | Approved | [1] | |
| Structure |
|
Click to Download Mol2D MOL |
||
| Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | ||||
| Formula |
C27H44O3
|
|||
| PubChem CID | ||||
| Canonical SMILES |
CC(CCCC(C)(C)O)C1CCC2C1(CCCC2=CC=C3CC(CC(C3=C)O)O)C
|
|||
| InChI |
1S/C27H44O3/c1-18(8-6-14-26(3,4)30)23-12-13-24-20(9-7-15-27(23,24)5)10-11-21-16-22(28)17-25(29)19(21)2/h10-11,18,22-25,28-30H,2,6-9,12-17H2,1,3-5H3/b20-10+,21-11-/t18-,22-,23-,24+,25+,27-/m1/s1
|
|||
| InChIKey |
GMRQFYUYWCNGIN-NKMMMXOESA-N
|
|||
| CAS Number |
CAS 32222-06-3
|
|||
| TTD Drug ID | ||||
| DrugBank ID | ||||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug | ||||||
| Arsenic trioxide | Realgar and orpiment | Click to Show/Hide the Molecular Data of This NP | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [2] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Up-regulation | Expression | BAX | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | BCL-2 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | CASP3 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | HL-60 | CVCL_0002 | Adult acute myeloid leukemia | Homo sapiens | ||
| K-562 | CVCL_0004 | Chronic myelogenous leukemia | Homo sapiens | |||
| Experimental
Result(s) |
Low-dose 1,25-dihydroxyvitamin D3 combined with arsenic trioxide synergistically inhibits proliferation of acute myeloid leukemia cells by promoting apoptosis. | |||||
| Beta carotene | Daucus carota | Click to Show/Hide the Molecular Data of This NP | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [3] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| In-vitro Model | EC9706 | CVCL_E307 | Esophageal squamous cell carcinoma | Homo sapiens | ||
| Experimental
Result(s) |
These two agents in combination synergistically inhibited cell growth and induced apoptosis. | |||||
| Bufalin | Bufo gargarizans | Click to Show/Hide the Molecular Data of This NP | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [4] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Up-regulation | Expression | CYP24A1 | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Expression | VDR | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | HL-60 | CVCL_0002 | Adult acute myeloid leukemia | Homo sapiens | ||
| Experimental
Result(s) |
Bufalin in combination with 1,25(OH)(2)D(3) enhanced the expression of VDR target genes, such as CYP24A1 and cathelicidin antimicrobial peptide, and effectively induced differentiation phenotypes. | |||||
| Carnosic acid | Salvia rosmarinus | Click to Show/Hide the Molecular Data of This NP | ||||
| Augmenting Drug Sensitivity | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [5] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Up-regulation | Phosphorylation | c-RAF | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Phosphorylation | ERK1 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Phosphorylation | ERK2 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Phosphorylation | MEK1 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Phosphorylation | RSK1 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | HL-60 | CVCL_0002 | Adult acute myeloid leukemia | Homo sapiens | ||
| Experimental
Result(s) |
Carnosic acid potentiates the antioxidant and prodifferentiation effects of 1alpha,25-dihydroxyvitamin D3 in leukemia cells but does not promote elevation of basal levels of intracellular calcium. | |||||
| Curcumin | Hellenia speciosa | Click to Show/Hide the Molecular Data of This NP | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [6] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Up-regulation | Expression | CYP24A1 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | CYP27B1 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | GPX1 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | ITGB3 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | MBCDF | Breast cancer | Homo sapiens | |||
| Experimental
Result(s) |
The concomitant administration of calcitriol with curcumin synergistically promoted anticancer effects in vitro and in vivo. | |||||
| Genistein | Glycine max | Click to Show/Hide the Molecular Data of This NP | ||||
| Augmenting Drug Sensitivity | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [7] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Down-regulation | Expression | CYP24A1 | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Expression | VDR | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | DU145 | CVCL_0105 | Prostate carcinoma | Homo sapiens | ||
| Experimental
Result(s) |
Genistein potentiates the antiproliferative actions of 1,25(OH)2D3 in DU145 cells by two mechanisms: (i) an increase in the half-life of 1,25(OH)2D3 due to the direct inhibition of CYP24 enzyme activity and (ii) an amplification of the homologous up-regulation of VDR. | |||||
| Yomogin + Tretinoin | Click to Show/Hide the Molecular Data of This NP | |||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [9] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| In-vitro Model | HL-60 | CVCL_0002 | Adult acute myeloid leukemia | Homo sapiens | ||
| Experimental
Result(s) |
Yomogin may be useful in combination with 1,25-(OH)(2) D(3) or all- trans-RA in the differentiation therapy for myeloid leukemias. | |||||
| β. A List of Natural Product(s) Able to Reverse the Resistance of This Drug | ||||||
| Silibinin | Carduus marianus | Click to Show/Hide the Molecular Data of This NP | ||||
| Reversing Drug Resistance | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [8] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Down-regulation | Expression | SNAI1 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | SNAI2 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | VDR | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | HT-29 | CVCL_0320 | Colon adenocarcinoma | Homo sapiens | ||
| SW480R | CVCL_AT68 | Colon adenocarcinoma | Homo sapiens | |||
| Experimental
Result(s) |
Silibinin restored 1,25D responsiveness in vitamin D-resistant colon cancer cells by downregulation of Snail1 and Snail2 and upregulation of vitamin D receptor. | |||||
| Target and Pathway | ||||
|---|---|---|---|---|
| Target(s) | Vitamin D3 receptor (VDR) | Molecule Info | [10] | |
| KEGG Pathway | Endocrine and other factor-regulated calcium reabsorption | Click to Show/Hide | ||
| 2 | Mineral absorption | |||
| 3 | Tuberculosis | |||
| NetPath Pathway | IL4 Signaling Pathway | Click to Show/Hide | ||
| Panther Pathway | Vitamin D metabolism and pathway | Click to Show/Hide | ||
| Pathway Interaction Database | Regulation of nuclear SMAD2/3 signaling | Click to Show/Hide | ||
| 2 | Direct p53 effectors | |||
| 3 | RXR and RAR heterodimerization with other nuclear receptor | |||
| 4 | Retinoic acid receptors-mediated signaling | |||
| 5 | Validated transcriptional targets of deltaNp63 isoforms | |||
| 6 | Validated transcriptional targets of TAp63 isoforms | |||
| Reactome | Nuclear Receptor transcription pathway | Click to Show/Hide | ||
| WikiPathways | Ovarian Infertility Genes | Click to Show/Hide | ||
| 2 | Nuclear Receptors in Lipid Metabolism and Toxicity | |||
| 3 | Nuclear Receptors Meta-Pathway | |||
| 4 | Vitamin D Receptor Pathway | |||
| 5 | Drug Induction of Bile Acid Pathway | |||
| 6 | Nuclear Receptors | |||
| 7 | Vitamin D Metabolism | |||